Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

11/11/2011

Paris, France and Mechelen, Belgium; 3 October 2011 – Servier, and Galapagos NV announced today that they have entered into a multi-year strategic alliance to develop new cancer therapies. 

The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos, a European biotechnology company specialized in the discovery and development of molecules with novel modes-of-action, will be responsible for the discovery and development of new candidate drugs against these targets. Servier will have an exclusive option to license each small molecule program after the completion of pre-clinical development by Galapagos. Upon exercise of each option, Servier will be responsible for further clinical development, registration and commercialization. Galapagos retains exclusive rights for clinical development, registration and commercialization in the United States.

Under the terms of the agreement, Galapagos will receive research access payments of €2 million from Servier. Galapagos is also eligible to receive discovery, development, regulatory and other milestone payments that could reach €260 million, plus royalties upon commercialization of products by Servier.

“Galapagos continues to deliver the innovation that research-based pharma companies are seeking to complement their pipelines. In this new alliance, Servier and Galapagos combine both their oncology targets and their capabilities in cancer drug discovery,” said Onno van de Stolpe, CEO of Galapagos. 

“Based on the progress made already in our osteoarthritis collaboration with Galapagos, we are convinced of Galapagos’ ability to deliver new cancer drugs based on novel targets. This alliance complements our very innovative cancer pipeline and is in line with Servier’s commitment to develop new treatments for sufferers of uncured diseases,” said Emmanuel Canet, Head of R&D at Servier.

“We are pleased to start this collaboration in oncology with Galapagos. Combination of our capabilities will allow the accelerated development of new drugs against innovative targets, some of them coming directly from our exploratory research,” said Stéphane Depil, MD, PhD, in charge of Oncology R&D at Servier.